Clinical-demographic markers for improving diabetes mellitus diagnosis in people with tuberculosis in Tanzania

Kenneth Cleophace Byashalira1,2*, Nyasatu Godfrey Chamba1,3, Yosra Alkabab5, Peter Masunga Mbelele2, Nyanda Elias Ntinginya6, Kaushik Laxmidas Ramaiya7, Mohamed Zahir Alimohamed7,8, Scott Kirkland Heysell5, Blandina Theophil Mmbaga1,3,4, Ib Christian Bygbjerg9, Dirk Lund Christensen9, Stellah George Mpagama1,2†, Troels Lillebaek9,10† and ADEPT Consortium

Abstract

Background: Tuberculosis (TB) control is threatened by an increasing prevalence of diabetes mellitus (DM), particularly in endemic countries. Screening for DM is not routinely implemented in Tanzania; therefore, we aimed to screen for DM at TB diagnosis using clinical-demographic markers.

Methods: Our cross-sectional study recruited TB patients who received anti-TB treatment between October 2019 and September 2020 at health care facilities in three regions from Tanzania. Patients were screened for DM using DM symptoms (polydipsia, polyphagia and polyuria) and random blood glucose (RBG) testing. Patients with a history of DM and those with no history of DM but an RBG \(\geq 7.8\) mmol/L had point-of-care glycated haemoglobin (HbA1c) testing, and were considered to have DM if HbA1c was \(\geq 48\) mmol/mol.

Results: Of 1344 TB patients, the mean age was 41.0 (± 17.0) years, and 64.7% were male. A total of 1011 (75.2%) had pulmonary TB, and 133 (10.4%) had at least one DM symptom. Overall, the prevalence of DM was 7.8%, of which 36 (2.8%) TB patients with no history of DM were newly diagnosed with DM by RBG testing. TB/DM patients were older than those with only TB (50.0 ± 14.0 years vs 40.0 ± 17.0 years, p < 0.001). Patients with RBG \(\geq 7.8\) mmol/L were more likely to have pulmonary TB (p = 0.003), age \(\geq 35\) years (p = 0.018), and have at least one DM symptom (p < 0.001). There was a substantial agreement (Kappa = 0.74) between the on-site glucometer and point-of-care HbA1c tests in detecting DM range of hyperglycemia.

Conclusion: The implementation of clinical-demographic markers and blood glucose screening identified the overall prevalence of DM and those at risk of DM in TB patients. Clinical-demographic markers are independent predictors for DM range hyperglycemia and highlight the importance of further diagnostic testing and early co-management of TB and DM.

Keywords: Implementation, DM screening, TB patients, Clinical-demographic, Tanzania

Introduction

Although tuberculosis (TB) incidence is decreasing worldwide, the rapid increase of diabetes mellitus (DM) prevalence, particularly in TB endemic settings, threatens to dismantle the gains achieved in TB control [1–3]. In 2019, the World Health Organization (WHO)
estimated 10 million people had active TB disease [4]. In the same year, 15% of individuals with TB had DM [5, 6]. In sub-Saharan Africa, the burden of TB is estimated to be 2.5 million, of which dual TB/DM contributes 9.0% [7, 8]. There has been a reported a three-fold increased risk of developing active TB for individuals with DM compared to those without [9, 10], a dual TB/DM disease contributing to poor TB treatment outcomes including increased treatment failures and increased mortality [9, 11]. Additionally, the clinical presentation of TB symptoms is reportedly more frequently non-specific for dual TB/DM disease resulting in delayed presentation and/or recognition by providers for testing [2, 12]. Despite the 2011 WHO recommendation of bidirectional screening for both DM and TB, most TB endemic settings, including Tanzania [13], have not fully implemented this practice in clinical settings [14, 15]. Tanzania has adopted WHO guidance and developed a local guideline for collaborative TB and DM care activities, including recommendations for bidirectional screening of TB and DM epidemics [13], however potential barriers to practical implementation include a lack of training of health care providers, a lack of availability of DM diagnostic tools such as glucometers at TB clinics, and a lack of studied benefit of any implementation approach [5, 14–16]. For instance, a readiness assessment conducted in Tanzania found less than one-third of health care providers possessed skills for TB/DM diagnosis and co-management, and only 7% of 30 health facilities at various levels (health centres, districts hospitals and regional referral hospitals) had glucometers accessible for TB clinics. There were no organized bidirectional TB and DM services at any of the health care facilities [15, 17].

In response to the stark findings of the readiness assessment, we designed an Adaptive Disease control Expert Programme model in Tanzania (ADEPT) to guide the country to integrate DM screening and care into the TB health care services [18]. Our initial plan included integrating dual screening and linkage of TB and DM in the health system, and increasing the training of health care providers regarding DM screening using diagnostic equipment such as glucometers with gluco-strips and glycated haemoglobin (HbA1c) at various levels of health facilities [18]. The aim was to perform DM screening at the TB clinic according to the Ministry of Health, Community Development, Gender, Elderly and Children’s national guideline for TB/DM collaborative care [13].

However, Tanzania is a low-middle income country, with the majority of people with TB living in considerable poverty [15]. Systems of TB care are guided by restricted budgets and the allocation of resources determined well in advance of distribution [19]. Strategies to more effectively implement a TB/DM diagnostic and management guideline are therefore of utmost importance. The current algorithm for TB/DM diagnosis has not been formally studied in Tanzania and is somewhat based on extrapolation from other recommendations on the topic. Additionally, the current algorithm does not include steps for potential triage, such as questions related to the classical symptoms of advanced DM disease, polyphagia, polydipsia, and polyuria that signify intracellular glucose deficiency [20]. Furthermore, there are no age-specific recommendations for DM screening among active TB patients in Tanzania, as suggested in other countries such as India, to increase the detection of DM in older age individuals in whom DM is more common [21]. We, therefore, sought to assess the feasibility and yield of DM screening in active TB patients across all health facilities in three different geographic regions in Tanzania based on other clinical and demographic characteristics for predicting DM range hyperglycaemia.

**Methods**

**Study settings**
The study was implemented in health facilities located in three regions in Tanzania: Dar es Salaam, Iringa and Kili manjaro. Dar es Salaam is the largest city located in the Eastern zone of Tanzania, with an estimated population of 4.4 million inhabitants by the 2012 census [22] and an annual growth rate of 5.6% [23]. Dar es Salaam is the major contributor to TB incidence, with 18% of the new TB patients diagnosed annually [24]. Iringa in southern-central Tanzania has the 2nd highest TB incidence due to a higher HIV/AIDS prevalence rate. Kilimanjaro, located in northern Tanzania, has a high prevalence of glucose impairment in the general population of 21.7% [25], but importantly Kilimanjaro borders with Kenya to the north and supports migrant populations with different access to healthcare services.

**Study design and population**
The study employed a cross-sectional design to screen for DM in patients with active TB (both newly diagnosed TB and patients receiving TB treatment). The TB patients were defined based on the National Tuberculosis and Leprosy Program guideline in Tanzania. In each region, all TB patients of all forms, diagnosed from October 2019 to September 2020 (1 year), were included in our study. A total of 32 health facilities [regional referral hospitals (n = 3), district hospitals (n = 7) and health centres (n = 22)] offering TB diagnosis and treatment, with or without DM services, were systematically selected for DM screening procedures. The study was granted ethical approval by the Kilimanjaro Christian Medical University College (Ref No. 2482) and the National Institute for Medical Research in Tanzania (NIMR/HQ/R.8a/Vol.
or absence of DM symptoms, using the POC glucometer machine with glucose test strips (Glucopor™ Inc; 2323 Halpern, Ville St-Laurent, Canada), and HbA1c analyser (HemoCue Hb1c 501 system—HemoCue AB; SE-262 23, Ängelholm, Sweden), a portable point of care device which is not affected by TB induced hyperglycaemia, and does not require a fasting state [2] with HbA1c cartridges. Printed screening algorithms also guided health care providers for DM screening in patients with TB. All the tools were free of charge supplied by the ADEPT programme.

DM screening procedures in patients with TB

All registered TB patients were asked if they had a known history of DM and were prescribed DM medications. In patients with a known history of DM, medical charts were reviewed to confirm the prescribed DM medications, followed by a point of care (POC) HbA1c testing to assess their glycaemic severity regardless of whether they had been prescribed DM medications. Patients were then provided context-tailored education about glycaemic control and adherence strategies for TB and DM medications.

TB patients with no history of DM were asked about the presence or absence of any DM symptoms: polyphagia, polydipsia and polyuria [2], followed by random blood glucose (RBG) testing regardless of the presence or absence of DM symptoms, using the POC glucometer machine. We classified patients’ blood glucose levels as normal (RBG < 7.8 mmol/L), pre-DM (RBG > 7.8–11.0 mmol/L) and DM (RBG ≥ 11.1 mmol/L) as per the International Diabetes Federation and the national TB/DM guidelines [20]. Next, TB patients without a known history of DM who had RBG levels in either the pre-DM or DM range were offered POC HbA1c testing. Validation of the HbA1c test was performed using control samples. Venous blood samples (4 µL) were collected using EDTA tubes and analysed within 5 min. HbA1c results were reported as mmol/mol and interpreted as <39 mmol/mol (normal), 39 to <48 mmol/mol (pre-DM) and ≥ 48 mmol/mol as (DM) [2].

Data management and statistical analysis

A standardized data sheet was used to collect patients’ demographics and clinical information. De-identified data and appropriate statistical methods were analysed with the IBM SPSS version 24 (IBM SPSS, Armonk, NY, USA). Mean with standard deviation (SD) or median with the 25th and 75th interquartile range (IQR) were used to summarize parametric and non-parametric continuous variables. Comparison of categorical variables such as frequencies and proportions of participants screened and diagnosed for normoglycaemia, hyperglycaemia (pre-DM or DM) were performed using the Pearson Chi-square or Fisher’s exact test. Independent t-test and Mann–Whitney U-tests were used to compare parametric and non-parametric continuous variables, including age, weight, RBG, and HbA1c levels, respectively. A multivariate logistic regression analysis was performed to calculate the odds ratio (OR) with 95% confidence intervals (CI) for risk factors that predicted DM range RBG levels in patients without a history of DM. A p-value of <0.05 was considered statistically significant.

Results

Baseline characteristics of study participants

7336 participants were registered at TB clinics from all recruitment sites during the study period (Fig. 1), including 4359 TB patients registered in Dar es Salaam study sites and 1384 TB patients from Iringa sites and 1593 patients in Kilimanjaro sites. Overall, DM screening from all the implementation sites was performed in 1344 (18.3%) TB patients and was included for the final analysis. Dar es Salaam region screened for DM in 744 (17.0%) of total TB patients registered in the area, Iringa screened 330 (23.8%), and Kilimanjaro 220 (13.8%).

Of the 1344 participants screened for DM, 870 (64.7%) were men, and the mean age was 41 (± 17) years (Table 1). 1303 (96.9%) had no previous history of TB, 680 (50.6%) had bacteriologically positive TB disease diagnosed by Xpert MTB/RIF and/or sputum smear microscopy tests, and 335 (25%) were living with HIV, of which 308 (91.9%) were on antiretroviral therapy (ART). Furthermore, 69 (5.1%) TB patients reported a history of DM and were
older compared to TB patients without a history of DM (50.0 ± 15.0 versus 41.0 ± 17.0 years, p < 0.001).

Characteristics of TB participants without prior history of DM screened for diabetes using RBG levels

The overall DM prevalence in 1344 participants was 7.8% (n = 105), including 36 (2.8%) with newly diagnosed DM patients by RBG testing. Table 2 summarizes the clinical characteristics of 1275 TB patients without a known history of DM who were screened for DM symptoms, followed by RBG, and then HbA1c tests if the RBG was in the pre-DM or DM range. All 1275 had both symptom testing and RBG testing. Overall, 133 (10.4%) of the 1275 TB patients had at least one DM symptom, including polydipsia in 51 (4%), polyphagia 72 (5.6%) and polyuria in 99 (7.8%). RBG diagnosed DM and pre-DM range hyperglycaemia in 36 (2.8%) and 82 (6.4%) patients, respectively. Of the people newly diagnosed with DM, Dar es Salaam region contributed 50.0%, Iringa and Kilimanjaro regions each contributed 25.0% of new DM cases. Furthermore, the sites in Dar es Salaam region, Iringa region, and Kilimanjaro region diagnosed DM in 18 (2.6%), 9 (2.8%), and 9 (4.4%) of the total TB patients screened for DM, respectively.

The mean age of participants with DM range glycaemia by RBG was (50.0 ± 14.0) years, and their weight was significantly higher (61.0 ± 16.0 kg) compared to TB patients with normal RBG levels (51.0 ± 13.0 kg) (p = 0.001). The proportion of pre-DM was significantly higher in men (78%) versus women (12%) compared to those with normoglycaemia (p = 0.011). Still, these differences were not significant when comparing those with DM range hyperglycaemia and normoglycaemia. Eighty-nine (75.4%) participants with DM and pre-DM were assessed for
glycaemic severity using the HbA1c test (Fig. 1). There was a substantial agreement between glucometer and HbA1c tests (Kappa = 0.74).

**Risk factors associated with high RBG levels in TB patients**

In multivariate regression of patients without a known history of DM, TB patients who presented with at least one of the DM symptoms (OR 23.07, 95% CI 13.94–39.09, p < 0.001) had an age of ≥35 years (OR 2.16, 95% CI 1.35–3.55, p = 0.018), or had pulmonary TB disease only (OR 3.05, 95% CI 1.57–6.09, p = 0.003) were significantly more likely to have RBG in the DM range (Table 3).

**Discussion**

Our study examined the implementation of clinical-demographic markers and blood glucose screening to guide the identification of people at risk of DM among those presenting with active TB disease in three diverse regions in Tanzania. Our major findings were that among people without a known history of DM, the presence of classical symptoms of DM (polyphagia, polydipsia and polyuria), age ≥35 years, and exclusive pulmonary TB were significant predictors of DM range RBG. These subgroups may represent the highest yield for additional confirmatory testing, such as with HbA1c.

The overall DM prevalence of 7.8% among patients with active TB, including those with a known prior diagnosis of DM, was lower than other previous studies of people with TB performed in Dar es Salaam (9.7%) [26] and Mwanza (16.7%) [27] regions of Tanzania, but more than twice as high the estimated 3.2% of the general population in the country [28]. This variation in DM prevalence in our study is likely due to the differences in populations with TB previously tested and the methods of DM screening. For instance, participants included in the study by Faurholt-Jepsen et al. from Mwanza region-Tanzania had bacteriologically confirmed TB only and might thus have been at higher risk of DM compared to clinically diagnosed TB patients [2]. Our findings are in accordance with the DM prevalence among TB patients reported from China (7.7%) [29], but lower than the pooled sub-Saharan African report and other studies conducted on DM prevalence among TB patients [3, 6, 7, 30–33]. The variation in DM prevalence across these studies and ours might be explained by differences in sample size, population, local setting, TB burden across the regions, and methods used for DM diagnosis. For

### Table 1 Characteristics of study participants with and without a history of diabetes (N = 1344)

| Characteristics                      | Total N = 1344 (%) | History of DM N = 69 (%) | No history of DM N = 1275 (%) | p-valuea |
|--------------------------------------|-------------------|--------------------------|-------------------------------|----------|
| Mean age (± SD) year                 | 50 (± 15)         | 41 (± 17)                |                               | <0.001   |
| Mean weight (± SD) kg                | 61 (± 14)         | 52 (± 13)                |                               | <0.001   |
| Sex                                  |                   |                          |                               | 0.085    |
| Female                               | 474 (35.3)        | 31 (44.9)                | 443 (34.7)                    |          |
| Male                                 | 870 (64.7)        | 38 (55.1)                | 832 (65.3)                    |          |
| HIV status (n = 1342)                |                   |                          |                               | 0.074    |
| Positive                             | 335 (25.0)        | 18 (26.5)                | 317 (24.9)                    |          |
| Negative                             | 1007 (75.0)       | 50 (73.5)                | 957 (75.1)                    |          |
| On ART (n = 335)                     |                   |                          |                               | 0.168    |
| Yes                                  | 308 (91.9)        | 15 (83.3)                | 293 (92.4)                    |          |
| No                                   | 27 (8.1)          | 3 (16.7)                 | 24 (7.6)                      |          |
| Location of TB disease               |                   |                          |                               | 0.754    |
| PTB                                  | 1011 (75.2)       | 53 (76.8)                | 958 (75.1)                    |          |
| EPTB                                 | 333 (24.8)        | 16 (23.2)                | 317 (24.9)                    |          |
| Bacteriological resultsb             |                   |                          |                               | 0.822    |
| Positive                             | 680 (50.6)        | 34 (49.3)                | 646 (50.7)                    |          |
| Negative                             | 664 (49.4)        | 35 (50.7)                | 626 (49.3)                    |          |
| TB history                           |                   |                          |                               | 0.464    |
| New TB                               | 1303 (96.9)       | 66 (95.7)                | 1237 (97.0)                   |          |
| Recurrent TB                         | 41 (3.1)          | 3 (4.3)                  | 38 (3.0)                      |          |

**Notes**

- TB: tuberculosis
- DM: diabetes mellitus
- SD: standard deviation
- PTB: pulmonary tuberculosis
- EPTB: Extra-pulmonary tuberculosis
- HIV: human immunodeficiency virus
- ART: antiretroviral therapy
- a Two participants had unknown HIV status
- b Diagnosed by Xpert MTB/RIF and/or sputum smear tests
instance, the background rate of DM in the general population of India is much higher than in Tanzania and most of the African continent and likely explains the differences in screening yield in studies from the Indian subcontinent compared to those in sub-Saharan Africa [30, 34].

DM symptoms (polyuria, polyphagia and polydipsia) have been established as cardinal symptoms for presuming DM, particularly type 2 DM, in the general population [2]. Our study observed that only 10% of participants reported yes to at least one DM symptom at baseline, yet 61% of DM cases had at least one of these symptoms. Our study findings in the Tanzanian context importantly differ from other reports that have previously suggested that DM symptoms are non-specific to individuals with TB/DM [2, 9]. Our findings highlight context-specific screening of TB patients and the use of classical DM symptom screening as a relatively high-yield and low-cost starting point for further triage to another diagnostic testing. For instance, our study demonstrated that implementation of this algorithm increased the yield of DM detection in TB patients by an absolute 3%, and notably, those patients were rapidly given disease information and triaged to DM tailored management. These findings are in keeping with a report from Nigeria in which implementation of the algorithm not only increased DM diagnostic yield but also proved feasible and acceptable among health care providers [35].

Variations in contexts across epidemiological settings may be essential to generate local demo-clinical markers, which are cost-effective to both implementers and patients for optimal DM screening in patients with TB. Several studies have reported age above 40 years as a non-modifiable risk factor for DM [6, 29, 31, 35].

### Table 2 Characteristics of tuberculosis participants screened for diabetes mellitus by random blood glucose excluding previously known diabetic patients (N = 1275)

| Characteristics | DM (≥ 11.1) N = 36 (%) | p-value | Pre-DM (7.8–11.0) N = 82 (%) | Normal (<7.8) Reference N = 1157 (%) | p-value |
|----------------|------------------------|---------|-----------------------------|--------------------------------------|---------|
| Mean age (± SD) year | 50 (± 14) | 0.001 | 46 (± 18) | 40 (± 17) | 0.001 |
| Mean weight (± SD) kg | 61 (± 16) | 0.001 | 55 (± 15) | 51 (± 13) | 0.064 |
| Sex | | | | | |
| Female | 15 (41.7) | 0.376 | 18 (22.0) | 410 (35.4) | 0.011 |
| Male | 21 (58.3) | | 64 (78.0) | 747 (64.6) | |
| HIV status | | | | | |
| Positive | 8 (22.2) | 0.710 | 18 (22.0) | 291 (25.2) | 0.518 |
| Negative | 28 (77.8) | | 64 (78.0) | 866 (74.8) | |
| On ART (n = 317) | | | | | |
| Yes | 8 (100) | 0.473 | 14 (77.8) | 267 (91.8) | 0.063* |
| No | 0 (0) | | 4 (22.2) | 24 (8.2) | |
| Type of TB | | | | | |
| PTB | 28 (77.8) | 0.710 | 68 (82.9) | 862 (74.5) | 0.095 |
| EPTB | 8 (22.2) | | 14 (17.1) | 295 (24.5) | |
| TB history | | | | | |
| New TB | 35 (97.2) | 0.942 | 80 (97.6) | 1122 (97.0) | 0.551* |
| Recurrent TB | 1 (2.8) | | 2 (2.4) | 35 (3.0) | |
| Bacteriological status | | | | | |
| Positive | 17 (47.2) | 0.675 | 47 (57.3) | 582 (50.3) | 0.219 |
| Negative | 19 (52.8) | | 35 (42.7) | 575 (49.7) | |
| DM symptoms | | | | | |
| Polydipsia (Yes, n = 51) | 12 (33.3) | <0.001 | 10 (12.2) | 29 (2.5) | <0.001 |
| Polyphagia (Yes, n = 72) | 13 (36.1) | <0.001 | 24 (29.3) | 35 (3.0) | <0.001 |
| Polyuria (Yes, n = 99) | 18 (50.0) | <0.001 | 32 (39.0) | 49 (4.2) | <0.001 |
| ≥ One DM symptoms | | | | | |
| Yes | 22 (61.1) | <0.001 | 37 (45.1) | 74 (6.4) | <0.001 |
| No | 14 (38.9) | | 45 (54.9) | 1083 (93.6) | |

RBG: Random blood glucose
* Fisher’s Exact test was used
was expected that we observed that TB patients identified with DM range RBG or with a known history of DM were significantly older than those with TB alone, similar to other studies of DM screening among people with TB [36]. Our analyses used an age cut-off of ≥ 35 years to identify those at higher risk of DM range RBG. A similar observation was made in a study from Zambia, where the mean age of people with DM and TB was 33 years [37]. In contrast, studies from other regions with lower TB prevalence have noted much older subgroups with TB/DM [38], highlighting the importance of screening strategies based on the local epidemiological context [2].

Furthermore, our study observed that pulmonary TB was associated with a higher RBG range in TB patients compared to those patients with extra-pulmonary TB. This finding is consistent with other studies, which have found, on average, a threefold higher risk of DM in pulmonary TB patients compared to those with extra-pulmonary TB [31, 39, 40]. Other evidence has shown that TB patients with concurrent DM present clinically with more pulmonary cavities [41] than patients with TB alone, resulting in a higher sputum bacterial load [42].

Our study found that 26 (7.8%) TB/HIV co-infected participants had DM, and three of them were not on ARTs. A prior study in Dar es Salaam observed that TB patients with HIV not on ART had a higher risk of developing DM than those on ART [43]. Other studies of TB observed that those living with HIV had a reduced risk of DM compared to those without HIV [27, 44]. Nevertheless, dual TB/DM and TB/HIV are known independent risk factors for poor TB treatment outcomes [43, 45, 46]. Therefore, given our findings of distinct subpopulations with TB/DM and TB/DM/HIV, further implementation studies in Tanzania should focus on early linkage to and retention in collaborative and multidisciplinary care.

We noted important regional differences in the uptake of the screening procedures and yield of diagnosing DM range RBG. We observed that only 17% of the total TB patients registered in Dar es Salaam, 23% in Iringa, and 14% in Kilimanjaro were screened for DM during the study period. The lack of screening uptake occurred

| Variables                        | Total N = 1275 | Unadjusted OR (95% CI) | p-value | Adjusted** OR (95% CI) | p-value |
|----------------------------------|----------------|------------------------|---------|------------------------|---------|
| Sex                              |                |                        |         |                        |         |
| Female                           | 44 (34.7)      | Reference              |         |                        |         |
| Male                             | 832 (65.3)     | 1.41 (0.93–2.15)       | 0.106   | 2.21 (1.33–3.70)        | 0.002   |
| Age group                        |                |                        |         |                        |         |
| < 35                             | 490 (38.5)     | Reference              |         |                        |         |
| ≥ 35                             | 785 (61.5)     | 2.14 (1.38–3.33)       | 0.001   | 2.16 (1.35–3.55)        | 0.018   |
| ≥ One DM symptoms                |                |                        |         |                        |         |
| No                               | 1148 (89.6)    | Reference              |         |                        |         |
| Yes                              | 133 (10.4)     | 14.64 (9.51–22.52)     | < 0.001 | 23.07 (13.94–39.09)     | < 0.001 |
| HIV status                       |                |                        |         |                        |         |
| Negative                         | 958 (75.1)     | Reference              |         |                        |         |
| Positive                         | 317 (24.9)     | 0.84 (0.53–1.33)       | 0.456   | 0.70 (0.41–1.17)        | 0.192   |
| On ART                           |                |                        |         |                        |         |
| No                               | 28 (91.2)      | Reference              |         |                        |         |
| Yes                              | 289 (8.8)      | 0.49 (0.16–1.55)       | 0.219   |                        |         |
| Location of TB                   |                |                        |         |                        |         |
| EPTB                             | 317 (24.9)     | Reference              |         |                        |         |
| PTB                              | 958 (75.1)     | 1.49 (0.92–2.42)       | 0.103   | 3.05 (1.57–6.09)        | 0.003   |
| TB history                       |                |                        |         |                        |         |
| New TB                           | 38 (3.0)       | Reference              |         |                        |         |
| Recurrent TB                     | 1237 (97.0)    | 1.20 (0.42–5.01)       | 0.769   | 1.06 (0.33–5.01)        | 0.925   |
| Bacteriological results          |                |                        |         |                        |         |
| Negative                         | 629 (49.3)     | Reference              |         |                        |         |
| Positive                         | 646 (50.7)     | 1.17 (0.80–1.71)       | 0.416   | 1.09 (0.65–1.85)        | 0.741   |

OR: Odds ratio, CI: confidence interval

**Adjusted for sex, age, DM symptoms, HIV, type of TB, TB registration group, and bacteriological results. Logistic regression analyses were used.**

Table 3: Multivariate analysis to assess factors associated with high RBG levels among TB patients without a known history of DM (N = 1275)
despite a refresher training conducted for health care providers on the procedures and inventory assurance for all necessary tools for DM screening. However, our findings of these initial efforts are in line with other studies which have observed low uptake of DM screening during early practice change [14, 31, 47]. Lower than expected uptake of DM screening in our study may be explained by the fact that we implemented the study during the COVID-19 pandemic, where more resources and personnel were occupied with COVID-19 response activities. Nevertheless, a focused review of the screening procedures with front-line health care workers toward screening practice improvement is underway and beyond the scope of the current discussion.

A major strength of the study is the systematic implementation across three demographically different regions in Tanzania and the use of both diagnostic testing with RBG and HbA1c for assessing RBG severity, as well as the use of DM clinical symptoms. Yet given the implementation in routine clinical settings, the study had several potential limitations. First, a smaller than expected percentage of TB patients were screened for DM, which raises the possibility of selection bias if healthcare providers preferentially perform screening in those suspected to have DM. Secondly, analysis of the risk factors was based on the RBG results and not on the HbA1c. RBG has a lower sensitivity than HbA1c [48], and there is the potential of missing DM patients who present with wasting disease secondary to TB disease and did not have a DM range RBG at presentation, which otherwise would have underestimated the true prevalence of DM. Furthermore, RBG and HbA1c testing at the time of TB diagnosis do not fully differentiate transient TB disease-induced hyperglycaemia that resolves with TB treatment alone and may falsely overestimate DM prevalence if glycaemia screening is not performed at the end of TB treatment.

We have yet to perform longer-term follow-up in patients with DM range RBG or HgbA1c to determine the persistence of the hyperglycaemia phenotype and to determine late-stage TB treatment outcomes or DM-related complications. Lastly, we did not have height measures, and therefore we could not calculate body mass index (kg/m²), which may be a better measure for relative anthropometric categories than weight alone to predict the risk of developing DM.

**Conclusion**

Among patients with active TB in three representative regions in Tanzania, the overall prevalence of DM was 7.8%, and a further 6.4% were at high risk of DM based on pre-DM range RBG measurements at the time of TB diagnosis. Clinical-demographic markers such as at least one classic DM symptom, pulmonary TB, and age of 35 years or above were independent predictors for DM range RBG. These markers are recommended to prioritize further diagnostic testing and earlier co-management of hyperglycaemia and TB.

**Abbreviations**

ADEPT: Adaptive Diseases Control Expert Program in Tanzania; ART: Antiretroviral therapy; CI: Confidence intervals; COVID: Coronavirus disease; DM: Diabetes mellitus; EDTA: Ethylenediamine tetraacetic acid; EPTB: Extra-pulmonary tuberculosis; HbA1c: Glycated haemoglobin; HIV: Human immunodeficiency virus; NIMR: Nation Institute for Medical Research; OR: Odds ratio; POC: Point of care; PTB: Pulmonary tuberculosis; RBG: Random blood glucose; SD: Standard deviation; SPSS: Statistical package for the social science.

**Acknowledgements**

We acknowledge the participation of Dar es Salaam, Iringa and Kilimanjaro Regional Administrative and Local Government Authorities to grant permission to implement this study. We recognize all health care providers from respective health facilities for their assistance during recruitment and data collection. Finally, we acknowledge all participants for their voluntary participation in the study.

**ADEXP consortium members and their affiliations:**

Kenneth Byashalira—Kilimanjaro Christian Medical University College, Moshie, Tanzania, United Rep.; Kibongtoto Infectious Disease Hospital, Sanya Juu, Siha, Tanzania, United Rep.; Nyasatu Chamba—Kilimanjaro Christian Medical University College, Moshi, Tanzania, United Rep.; Kilimanjaro Christian Medical Centre, Moshi, Tanzania, United Rep.; Yosra Alkabab—Division of Infectious Diseases and International Health, University of Virginia, USA. Peter Mbellele—Kibongtoto Infectious Disease Hospital, Sanya Juu, Siha, Tanzania, United Rep.; Nyanda Ntinginya—National Institute of Medical Research, Mbeya Medical Research Centre, Mbeya, Tanzania, United Rep.; Kauhik Ramaia—Shree Hindu Mandal Hospital, Dar es Salaam, Tanzania, United Rep.; Mohamed Z. Alimohamed—Shree Hindu Mandal Hospital, Dar es Salaam, Tanzania, United Rep.; Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam. Scott Heyssel—Division of Infectious Diseases and International Health, University of Virginia, USA. Blandina T. Mmbaga—Kilimanjaro Christian Medical University College, Moshi, Tanzania, United Rep.; Kilimanjaro Christian Medical Centre, Moshi, Tanzania, United Rep.; Kilimanjaro Clinical Research Institute, Moshi, Tanzania, United Rep.; Bygbjerg—Global Health Section, Department of Public Health, University of Copenhagen, Denmark. Dirk L. Christensen—Global Health Section, Department of Public Health, University of Copenhagen, Denmark. Stellah Mpagama-Kilimanjaro Christian Medical University College, Moshi, Tanzania, United Rep.; Kibongtoto Infectious Disease Hospital, Sanya Juu, Siha, Tanzania, United Rep.; Troels Lillebaek—Global Health Section, Department of Public Health, University of Copenhagen, Denmark. International Reference Laboratory of Mycobacteriology Statens Serum Institut, Copenhagen, Denmark. Peter Mbelele—ADEPT consortium members and their affiliations: Muhimbili University of Health and Allied Sciences, Dar es Salaam. Scott Heyssel—Division of Infectious Diseases and International Health, University of Virginia, USA. Blandina T. Mmbaga—Kilimanjaro Christian Medical University College, Moshi, Tanzania, United Rep.; Kilimanjaro Christian Medical Centre, Moshi, Tanzania, United Rep.; Kilimanjaro Clinical Research Institute, Moshi, Tanzania, United Rep.; Ib C. Bygbjerg—Global Health Section, Department of Public Health, University of Copenhagen, Denmark. Dirk L. Christensen—Global Health Section, Department of Public Health, University of Copenhagen, Denmark. Stellah Mpagama—Kilimanjaro Christian Medical University College, Moshi, Tanzania, United Rep.; Kibongtoto Infectious Disease Hospital, Sanya Juu, Siha, Tanzania, United Rep.; Troels Lillebaek—Global Health Section, Department of Public Health, University of Copenhagen, Denmark. International Reference Laboratory of Mycobacteriology Statens Serum Institut, Copenhagen, Denmark. Jan Willem Affenaar—Rijksuniversiteit Groningen, Groningen, The Netherlands.

**Authors’ contributions**

Study design—KB, SM, TL, NC, BM, and DLC; provided technical inputs in the proposal—All authors; Secured the funding for the project from the Ministry of Foreign Affairs of Denmark—DLC, KB, SM, BM and KP; Fieldwork and data acquisition—KB, NC, PM; Data analysis and interpretation—KB, PM, YA, SM, DLC, TL, NC and SH; Writing, editing and submitting the manuscript—KB and inputs from all authors; All authors read and approved the final manuscript.

**Funding**

This implementation study was funded by the Danish Ministry of Foreign Affairs (Ref No. 17-03-UK). YA was supported by the American Society of Tropical Medicine and Hygiene/Burroughs Welcome Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Availability of data and materials**

Data used in this study are only available under restricted access through authors due to Tanzanian data protection legislation. However, data and
materials used in this manuscript will be available on request from the corresponding author.

**Declarations**

**Ethics approval and consent to participate**

The implementation study was approved by the ethics committee of Kilimanjaro Christian Medical University College, and the National Institute for Medical Research in Tanzania.

**Consent for publication**

Not applicable.

**Accordance statement**

All methods were carried out in accordance with relevant guidelines and regulations.

**Informed consent**

This is an implementation study, all participants involved in this study received care services as part of the standard of care according to the national guideline, and international standards for dual TB/DM collaborative services. Participants informed consent and data used in this study were waived by the National Health Research Ethics Review Committee at National Institute for Medical Research (Nat-HREC-NIMR) certificate number NIMR/HQ/R.8A/Vol. IX/2988 and the Kilimanjaro Christian Medical College Research Ethics and Review Committee at Kilimanjaro Christian Medical University College (CRERC-KCMUCo) certificate number 2482.

**Competing interests**

The authors declare no conflicts of interest, financial or otherwise.

**Author details**

1. Kilimanjaro Christian Medical University College, Moshi, United Republic of Tanzania.
2. Kilimanjaro Infectious Diseases Hospital, Sanya Juu, PO. Box: 12, Sihanda, Kilimanjaro, United Republic of Tanzania.
3. Kilimanjaro Christian Medical Centre, Moshi, United Republic of Tanzania.
4. Kilimanjaro Clinical Research Institute, Moshi, United Republic of Tanzania.
5. Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, USA.
6. National Institute of Medical Research, Mbeya Medical Research Centre, Mbeya, United Republic of Tanzania.
7. Shree Hindu Mandal Hospital, Dar es Salaam, United Republic of Tanzania.
8. Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania.
9. Division Global Health Section, Department of Public Health, University of Copenhagen, Copenhagen, Copenhagen, Denmark.
10. International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark.

Received: 8 September 2021   Accepted: 7 March 2022

Published online: 16 March 2022

**References**

1. Harries AD, Kumar AMV, Satyanarayana S, Lin Y, Kapur A, Zachariah R, et al. Addressing diabetes mellitus as part of the strategy for ending TB. Trans R Soc Trop Med Hyg. 2016;110(1):173–9.
2. Lin Y. Diabetes MELLITUS-TUBERCULOSIS a guide to the essential practice first edition. 2019.
3. Mahtemen MH, Bjune GA, Yimer SA. Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: a systematic review. PLoS ONE. 2017;12(4):e0175925. https://doi.org/10.1371/journal.pone.0175925.
4. World Health Organization (WHO). Global Tuberculosis Report 2019. Geneva: World Health Organization, 2019.
5. Mcmurry HS, Mendelsohn E. Coprevalence of type 2 diabetes mellitus and tuberculosis in low-income and middle-income countries: a systematic review. 2018;21:1280–7.
6. Mave V, Meshram S, Lokhande R, Kadam D, Dharmshale S, Bhardwaj R. Prevalence of dysglycemia and clinical presentation of pulmonary tuberculosis in Western India. Int J Tuberc Lung Dis. 2017;21(August):1280–7.
7. Alebel A, Wondemagegn AT, Tezema C, Kibret GD, Wagnew F, Petrucka P, et al. Prevalence of diabetes mellitus among tuberculosis patients in Sub-Saharan Africa: a systematic review and meta-analysis of observational studies. 2019(March).
8. Report A. Annual report. 2016.
9. Workneh MH, Bjune GA, Yimer SA. Diabetes mellitus is associated with increased mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients in South-Eastern Amhara Region Ethiopia. Infect Dis Poverty. 2016;5(1):45–54.
10. Faurskold-jepsen D, Range N, Prayog G, Jeremiah K, Faurskold- M, Aabye MG, et al. The association between conventional risk factors and diabetes is weak among urban Tanzanians. Diabetes Care. 2014;37(January):5–6.
11. Baker MA, Harries AD, Leon CY, Hart JE, Kapur A, Lonnooth K, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81.
12. Kansal HM, Srivastava S, Bhargava SK. REFERENCES. 2015;28(1):58–60.
13. Development C. National guidelines for collaborative care and control of tuberculosis and diabetes acknowledgment. 2018(June).
14. Soe TK, Soe KT, Satyanarayana S, Saw S, San CC, Aung ST. Gaps in implementing bidirectional screening for tuberculosis and diabetes mellitus in Myanmar: an operational research study. Trop Med Infect Dis. 2020;5(1):19.
15. Shayo FK. Availability and readiness of diabetes health facilities to manage tuberculosis in Tanzania: a path towards integrating tuberculosis-diabetes services in a high burden setting? 2019;1–7.
16. Suhuyini R, Id S, Hlongwana KB. Barriers and facilitators to bidirectional screening of TB-DM in Ghana: healthcare workers’ perspectives. PLoS ONE. 2020. https://doi.org/10.1371/journal.pone.0235914.
17. Mpagaema SG, Mbelele PM, Chongolo AM, Lekule IA, Lyimo JJ, Kibiki GS, et al. Gridlock from diagnosis to treatment of multidrug-resistant tuberculosis in Tanzania: low accessibility of molecular diagnostic services and lack of healthcare worker empowerment in 28 districts of 5 high burden TB regions with mixed methods evaluation. BMC Public Health. 2019;19(1):1–11.
18. Mpagaema SG, Ramaiya K, Lileeback T, Boer D, Ntinginya NE, Mmbaga BT, et al. Protocol for establishing an Adaptive Diseases control Expert Programme in Tanzania (ADEPT) for integrating care of communicable and non-communicable diseases using tuberculosis and diabetes as a case study. BMC Open. 2021;11:e0041521.
19. Mhalu G, Hella J, Nhimbira F, Said K, Mosabi T, Mlacha YP, et al. Pathways and associated costs of care in patients with confirmed and presumptive tuberculosis in Tanzania: a cross-sectional study. BMC Open. 2019;9(8):1–13.
20. Internation Diabetes Federation. IDF diabetes atlas Ninth. Dunia: IDF; 2019. p. 168.
21. Shidam UG, Roy G, Sahu SK, Kumar SV, Ananthanarayanan PH. Screening for diabetes among presumptive tuberculosis patients at a tertiary care centre in Pondicherry, India. Int J Tuberc Lung Dis. 2015;19(December):1163–8.
22. NBS. National Beaural of Statistics. 2012 population and housing census population distribution by administrative areas. Nat Bur Stat Minist Financ. 2012,56.
23. Faku P, Blanco B, Massagno A, Basel S. Comorbidity between comminable and non-communicable diseases: the example of the dual burden of tuberculosis and diabetes in Dar es Salaam, Tanzania. 2016.
24. United THE, OF R, Health MOF, Development C, Aids N, Programme C. the United Republic of Tanzania the National. 2019(January).
25. Stanifer JW, Clanden CR, Makuka GJ, Egger JR, Maro V, Maro H, et al. Prevalence, risk factors, and complications of diabetes in the Kilimanjaro region: a population-based study from Tanzania. PLoS ONE. 2016;11(10):1–13.
26. Munseri PJ, Kimambo H, Pallangyo K. Diabetes mellitus among patients attending TB clinics in Dar es Salaam: a descriptive cross-sectional study. BMC Infect Dis. 2019;19(1):915.
27. Faurskold-jepsen D, Range N, Prayog G, Jeremiah K, Faurskold- M, Aabye MG, et al. Diabetes is a risk factor for pulmonary tuberculosis: a case-control study from Mwanza, Tanzania. PLoS ONE. 2011;6(8):4–8.
28. Sunko ML, Mpagaema SG, Gratz J, Kisona R, Saidi Q, Kibiki GS, et al. Glycated hemoglobin screening identifies patients admitted for retreatment of tuberculosis at risk for diabetes in Tanzania. J Infect Dev Ctries. 2016;10(4):423–6.
29. Zhao Q, Xiao X, Lu W, Qiu L, Zhou C, Jiang W, et al. Screening diabetes in tuberculosis patients in eastern rural China: a community-based cross-sectional study. Int J Tuberc Lung Dis. 2016;20(January):1370–6.

30. Nouabiad JJ, Narusenwe JR, Nyaga UF, Nkeyck JK, Endomba FT, Kaze AD, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health. 2019;7(4):e448–60.

31. Hoa NB, Phuc PD, Hien NT, Hoa VQ, Thuong PH, Anh PT, et al. Prevalence and associated factors of diabetes mellitus among tuberculosis patients in Hanoi Vietnam. BMC Infect Dis. 2018;18:1–9.

32. Part T, Session D. Prevalence of diabetes among tuberculosis patients attending a tertiary care hospital. Dr. Afisa Habib Sheuly Bangladesh Institute of Health Sciences Department of Epidemiology and Biostatistics (Division of Public Health) Dhaka, Bangladesh. 2012;2011–2.

33. Pande T, Huddart S, Xavier W, Kulavalli S, Chen T, Pai M, et al. Prevalence of diabetes mellitus amongst hospitalized tuberculosis patients at an Indian tertiary care center: a descriptive analysis. 2018;1(3):e0200338.

34. Shivakumar SVC, Chandrasekaran P, Kumar AMV, Paradkar M, Dhanasekaran K. Diabetes and pre-diabetes among household contacts of tuberculosis patients in India: is it time to screen them all? Int J Tuberc Lung Dis. 2018;22(09):686–94.

35. Ekele N, Ukwaia KN, Chikwu JN, Nwafor CC, Meka AO, Egbagbe EE, et al. Screening for diabetes mellitus among tuberculosis patients in Southern Nigeria: a multi-centre implementation study under programme settings. Sci Rep. 2017;7(March):1–8.

36. Miththyunyan S, Wilson N, Satyanarayana S, Dewan PK. High Diabetes Prevalence among Tuberculosis Cases in Kerala, India. 2012;7(10):1–7.

37. Fwoloshi S, Hachaambwa LM, Chiyerfu KO, Chimwa L, Hoffman TW, Ngalamika O, et al. Screening for diabetes mellitus among tuberculosis patients: findings from a study at a Tertiary Hospital in Lusaka, Zambia. Can J Infect Dis Med Microbiol. 2018;2018:3524926.

38. Ko P, Lin S, Tu S, Hsieh M. High diabetes mellitus prevalence with increasing trend among newly-diagnosed tuberculosis patients in an Asian population: a nationwide population-based study. Prim Care Diabetes. 2015;10(375):148–55.

39. Garth A. Analysing data using SPSS (A practical guide for those unfortunate enough to have to actually do it). 2008.

40. Pavlovic JM, Pavlovic AD, Bulajic MV. Prevalence of diabetes mellitus (DM) in tuberculosis (TB) patients: clinical and radiologic features in the TB-DM association based on a five-year hospital study. Infez Med. 2018;26(1):22–7.

41. Li-kuei H, Liang-De J, Yi-Chun L, Mei-Han W, and Shi-Chuan C. Pulmonary Tuberculous Cavities in Diabetic Patients: Glycemic Control is Still the Dominant Factor Despite the Emerging Role of Metformin. J Chinese Med Assoc. 2019:1–22.

42. Mbelele PM, Sauli E, Mpolya EA, Mohamed SY, Addo K. TB or not TB?: definitive determination of species within the M. tuberculosis complex in unprocessed sputum from adults with presumed multidrug-resistant tuberculosis TB or not TB ? Definitive determination of species within the Mycobacterium tuberculosis. 2021;(June).

43. Kagaruki GB, Mayige MT, Ngadaya ES, Kimaro GD, Kalinga AK, Kilale AM, et al. And associated factors of diabetes mellitus among tuberculosis patients from Mwanza, Tanzania. Trop Med Int Health. 2013;18(7):822–9.

44. Shivakumar SVC, Chandrasekaran P, Kumar AMV, Paradkar M, Dharmasekaran K. Relapse tuberculosis TB or not TB?: Definitive determination of species within the Mycobacterium tuberculosis complex in unprocessed sputum from adults with presumed multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19(March):879–86.

45. Basir MS, Habib SS, Zaidi SMA, Khowaja S, Hussain H, Ferrand RA, et al. Operationizational of bi-directional screening for tuberculosis and diabetes in private sector healthcare clinics in Karachi, Pakistan. BMC Health Serv Res. 2019;7:1–9.

46. Harries AD, Kumar AMV, Satyanarayana S, Dewan PK. High Diabetes Prevalence among Tuberculosis Cases in Kerala, India. 2012;7(10):1–7.

47. Basir MS, Habib SS, Zaidi SMA, Khowaja S, Hussain H, Ferrand RA, et al. Operationalization of bi-directional screening for tuberculosis and diabetes in private sector healthcare clinics in Karachi, Pakistan. BMC Health Serv Res. 2019;7:1–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions